Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-28T00:50:57.949Z Has data issue: false hasContentIssue false
  • English
  • Français

Deprenyl: Protective vs. Symptomatic Effect

Published online by Cambridge University Press:  18 September 2015

Oscar S. Kofman
Oscar S. Kofman*
Affiliation:
Department of Medicine (Neurology), University of Toronto, Toronto
*
99 Avenue Road, Suite 608, Toronto, Ontario, Canada M5R 2G5
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Focus on Parkinson's Disease
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue 1 , February 1991 , pp. 83 - 85
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

1.Birkmayer, W, Riederer, P, Youdim, MBH, et al. The potentiation of the anti-kinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975; 36: 303–326.CrossRefGoogle Scholar
2.Lees, AJ, Kohout, LS, Shaw, KM, et al. Deprenyl in Parkinson’s dis-ease. Lancet 1977; 2: 791–795.CrossRefGoogle Scholar
3.Golbe, LI, Lieberman, AN, Muenter, MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol 1988; 11:45–55.CrossRefGoogle ScholarPubMed
4.Elizan, TS, Yahr, MD, Moros, DA. Selegiline as an adjunct to con-ventional levodopa therapy in Parkinson’s disease. Arch Neurol 1989; 46: 1280–1283.CrossRefGoogle Scholar
5.Birkmayer, W, Knoll, J, Riederer, P, et al. Increased life expectancy resulting from addition of L-deprenyl to madopar treatment in Parkinson’s disease: A long-term study. J Neural Transm 1985; 64: 113–27.CrossRefGoogle Scholar
6.Csanda, E, Tarczy, M. Selegiline in early and late phases of Parkinson’s disease. J Neural Transm 1987; Suppl 25: 105–114.Google ScholarPubMed
7.Elizan, TS, Yahr, MD, Moros, DA. Selegiline use to prevent progres-sion of Parkinson’s disease. Arch Neurol 1989; 46: 1275–1279.CrossRefGoogle Scholar
8.Myllyla, VV, Sotaniemi, KA, Tuominen, J, et al. Selegiline as prima-ry treatment in early phase Parkinson’s disease. Acta Neurol Scand 1989; 126: 177–182.CrossRefGoogle Scholar
9.Lieberman, A, Thompson, R, Fazzini, E, et al. Deprenyl: Long term experience. Abstract, Neurology 1990; 40 (Suppl 1): 153.Google Scholar
10.Tetrud, JW, Langston, JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.CrossRefGoogle ScholarPubMed
11.Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
12.Kofman, OS. Is deprenyl symptomatic or protective in Parkinson’s disease? Parkinson Network 1990; Bull. 54: 1–2.Google Scholar
13.Kofman, OS. Is deprenyl symptomatic or protective in Parkinson’s dis-ease? Author’s Comments, Parkinson Network 1990; Bull. 55: 2.Google Scholar
14.Kofman, OS. Antioxidative experimental therapies. Shoulson, I, ed. Discussion, First International Congress of Movement Disorders. Washington, D.C. Apr. 25, 1990.Google Scholar
15.Kofman, OS. Deprenyl. the protective vs. symptomatic effect. The national conference on Parkinson’s disease. Victoria, B.C., September8, 1990.Google Scholar
16.Landau, WM. Clinical neuromythology IX – pyramid sale in the bucket shop: Datatop Bottoms Out. Neurology 1990; 40: 1337–40.CrossRefGoogle ScholarPubMed
17.Sonsalla, PK, Golbe, LI. Deprenyl as prophylaxis against Parkinson’s disease? Clin Neuropharmacol 1988; 11: 500–511.CrossRefGoogle ScholarPubMed
18.Markham, CH, Diamond, SG. Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 1981; 31: 125–31.CrossRefGoogle Scholar
19.Knoll, J. Extension of life span of rats by long-term deprenyl treat-ment. The Mount Sinai Journal of Medicine 1988; 55: 67–74.Google Scholar